Clinical characteristics, treatment and prognosis of children with unilateral retinoblastoma and intracranial segment of Retrobulbar optic nerve invasion

Yi-Zhuo Wang¹, Yi Zhang¹†, Dong-Sheng Huang¹*, Ji-Tong Shi², Jian-Min Ma², Bin Li³, Xiao-Lin Xu³, Yan Zhou¹ and Hua-Li Gu¹

Abstract

Background: To analyze the clinical characteristics, treatment and prognosis of children with unilateral retinoblastoma (RB) and intracranial segment of retrobulbar optic nerve invasion.

Methods: A total of 14 children with unilateral RB and intracranial segment of retrobulbar optic nerve invasion were enrolled in this retrospective study from January 2009 to December 2018. Clinical characteristics, treatment and prognosis were collected and analyzed. Survival curves were calculated by Kaplan-Meier method.

Results: Of 14 cases, there were 7 male and 7 female, ranging in age from 22.85 to 121.97 months (median, 41.03 months). Seventy-one percent of patients came from first-tier cities in China and effected in the left eye. Magnetic resonance imaging (MRI) results indicated that all patients presented with thickened and enhanced optic nerve and intracranial segment of optic nerve invasion. Nine patients received comprehensive therapeutic regimen (chemotherapy, eye enucleation, radiotherapy and intrathecal therapy). The patients were followed up to December 2019, with a median follow-up of 20.6 months. The median disease specific survival was 48.99 ± 8.62 months, and the overall survival (OS) rate was 64.3%. Radiotherapy and comprehensive therapeutic regimen had significant impact on survival time (all \( p < 0.05 \)).

Conclusions: The overall prognosis of unilateral RB patients with intracranial segment of retrobulbar optic nerve invasion was poor. Chemotherapy and surgical treatment were necessary, but more attention should be paid to radiotherapy and intrathecal therapy for improving prognosis.

Keywords: Retinoblastoma, Optic nerve invasion, Intracranial segment of retrobulbar optic nerve, Prognosis

* Correspondence: hds5180@sina.com
† Yi-Zhuo Wang and Yi Zhang contributed equally to the manuscript and thus share the first authorship.
¹Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, No. 2, Xihuan South Road, Yizhuang Economic and Technological Development Zone, Beijing 100176, China

Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Retinoblastoma (RB) is the most common primary intraocular malignancy in children, but a rare paediatric cancer with a reported incidence worldwide of 1:15,000 to 1:20,000 live births [1]. RB is unilateral in about 60% of cases with a median age at diagnosis of two years [2]. Leukocoria is the most common initial presenting sign of RB which is seen in 60 to 80% of newly diagnosed patients, followed by strabismus [3, 4]. Diagnosis of RB is made by examination of the fundus under general anesthesia. Computed tomography (CT) scans, magnetic resonance imaging (MRI) and ultrasound are used to confirm the diagnosis and assess the local extension [5]. Prognosis and survival depends on early diagnosis and appropriate treatment.

China is the most populous country in the world and documents about 1000 new cases of RB every year, accounting for 1/8 of all cases worldwide [6]. Good medical conditions and modern technology have increased overall survival rate of RB to exceed 95% in developed countries [7]. However, in developing countries, patients with RB are mostly diagnosed at advanced stages [8]. Patients with advanced RB usually have poor prognosis, especially those with an intracranial segment of optic nerve invasion [9]. There is no special clinical manifestation in this kind of patients, but orbital MRI show that thickened and enhanced optic nerve invaded the intracranial segment [10]. In addition, the report of RB with intracranial segment of optic nerve invasion is extremely rare. Our hospital collects nearly 3000 cases of RB clinical data from January 2009 to December 2018, and screen out only 14 cases of unilateral RB patients with intracranial segment of retrobulbar optic nerve invasion. In this study, we aimed to retrospectively analyze the clinical characteristics, treatment and prognosis of children with unilateral RB and intracranial segment of retrobulbar optic nerve invasion.

Materials and methods

Patients

We retrospectively reviewed 14 children with unilateral RB and intracranial segment of retrobulbar optic nerve invasion from January 2009 to December 2018. The inclusion criteria were as follows: 1) Patients diagnosed with unilateral RB for the first time in our hospital; 2) patients with orbital magnetic resonance imaging (MRI) before chemotherapy suggesting invasion of the intracranial segment of retrobulbar optic nerve; 3) patients with age < 14 years; 4) patients undergoing chemotherapy, radiotherapy, surgery, intrathecal therapy and follow-up according to comprehensive treatment of our hospital. The exclusion criteria were as follows: 1) patients with trilateral RB; 2) patients with recurrent invasion of the intracranial segment of the optic nerve after treatment; 3) patients with distant metastasis of bone, bone marrow and lymph nodes at the time of diagnosis; 4) patients with severe congenital deficiency, including immune deficiency, liver and kidney patients, etc.; 5) patients with a family history of mental illness; 6) patients with a family history of RB. This study was approved by the ethics committee of the Beijing Tongren Hospital, Capital Medical University (number, TRECKY2019–034). Written informed consent was obtained from all participants and their guardians.

Diagnostic criteria

Orbital CT scan, orbital MRI, eye ultrasound and fundus examinations were performed in all patients. In addition, neuron specific enolase (NSE) in serum and cerebrospinal fluid (CSF) of patients were analyzed using the electroluminescence with the NSE Kit (Roche, US). Lactate dehydrogenase (LDH), a non-specific tumor marker, was detected by chemical immunoassay. The pathology examination of CSF was performed by hematoxylin eosin staining. In our hospital, all patients whose imaging or serology test showed RB were also undergoing bone marrow aspiration. If bone marrow involvement was confirmed, re-examination should be conducted every 3 months until complete remission of bone marrow.

Diagnosis of retinoblastoma was usually clear from presenting signs and clinical examination [10]. MRI was used to assess invasion of the optic nerve. All tumors were classified (stage 0-IV) according to the International Retinoblastoma Staging System (IRSS) proposed by Chantada et al. [11].

Therapy

Patients received chemotherapy, eye enucleation, radiotherapy or intrathecal therapy. Pre-surgical chemotherapy was sustained for 4–6 cycles, and 21 days were one

| Characteristic                          | Number (n, %) |
|----------------------------------------|--------------|
| Age (years), < 3/≥ 3                   | 3 (21.4)/11 (78.6) |
| Gender, M/F                            | 7 (50.0)/7 (50.0) |
| Eye affected, left/right               | 10 (71.4)/4 (28.6) |
| City, first-tier/second-tier           | 10 (71.4)/4 (28.6) |
| Presenting signs                       |              |
| Leukocoria                             | 6 (42.9)     |
| Strabismus                             | 3 (21.4)     |
| Others                                 | 5 (35.7)     |
| Time from first symptom to diagnosis (mo), median | 3.79 (0.1–17.35) |
| < 4 weeks                              | 3 (21.4)     |
| ≥ 4 weeks                              | 11 (78.6)    |

M male, F female, mo months
| No. | Gender | Age (years) | Eye affected | RB staging (IRSS) | Serum NSE (ng/dl) | NSE in CSF (ng/dl) | CSF cytology | serum LDH (U/L) | Total chemotherapy cycle | Radiotherapy | Radiotherapy dose (Gy) | Eye enucleation | Outcome | Time from first symptom to diagnosis (mo) | Cause of death |
|-----|--------|-------------|--------------|------------------|------------------|-------------------|--------------|-------------|----------------------|--------------|----------------------|-----------------|---------|-------------------------------|---------------|
| 1   | Male   | 2.24        | Left         | IV               | 31.6             | 126               | N            | 352.0       | 15.00                | No           | –                    | Yes             | Death   | 0.46                         | Meningeal metastasis |
| 2   | Female | 10.16       | Right        | IV               | 20.2             | 53                | N            | 2160        | 8.00                 | Yes          | 45.00                | Yes             | Survival | 2.07                         | –              |
| 3   | Male   | 2.50        | Right        | IV               | 35.6             | 123               | N            | 2900        | 12.00                | No           | –                    | Yes             | Death   | 7.95                         | Meningeal metastasis |
| 4   | Female | 3.44        | Left         | IV               | 23.1             | 127               | N            | 3120        | 12.00                | Yes          | 39.60                | Yes             | Survival | 0.30                         | –              |
| 5   | Male   | 4.81        | Right        | IV               | 20.8             | 172               | N            | 2500        | 14.00                | No           | –                    | Yes             | Survival | 1.87                         | –              |
| 6   | Male   | 3.40        | Left         | IV               | 26.3             | 125               | N            | 2970        | 7.00                 | Yes          | 48.80                | Yes             | Survival | 17.35                        | –              |
| 7   | Male   | 6.30        | Left         | IV               | 65.0             | 2947              | P            | 3110        | 6.00                 | Yes          | 45.00                | Yes             | Death   | 0.1                          | Meningeal metastasis |
| 8   | Female | 3.60        | Left         | IV               | 24.80            | 84                | N            | 1240        | 10.00                | No           | –                    | No              | Death   | 15.44                        | Meningeal metastasis |
| 9   | Male   | 3.28        | Left         | IV               | 15.7             | 84                | N            | 3590        | 14.00                | Yes          | 43.20                | Yes             | Survival | 2.56                         | –              |
| 10  | Female | 4.44        | Left         | IV               | 27.50            | 893               | P            | 2240        | 19.00                | Yes          | 43.20                | Yes             | Survival | 11.66                        | –              |
| 11  | Female | 1.90        | Left         | IV               | 21.0             | 65                | N            | 2560        | 9.00                 | Yes          | 39.60                | Yes             | Survival | 6.47                         | –              |
| 12  | Female | 3.07        | Left         | IV               | 21.0             | 85                | N            | 2240        | 15.00                | Yes          | 43.20                | Yes             | Survival | 5.19                         | –              |
| 13  | Female | 6.85        | Right        | IV               | 34.9             | 25.1              | N            | 2640        | 15.00                | Yes          | 43.20                | Yes             | Survival | 2.46                         | –              |
| 14  | Male   | 3.00        | Left         | IV               | 18.5             | 102               | N            | 2340        | 6.00                 | No           | –                    | No              | Death   | 5.03                         | Meningeal metastasis |

No number, mo month, NSE neuron specific enolase, CSF cerebrospinal fluid, LDH lactate dehydrogenase, N negative, P positive (small round malignant cells)
cycle of chemotherapy. Multi-drug combination chemotherapy was adopted in our therapy, including vincristine (age < 3 years, 0.05 mg/kg; age ≥ 3 years, 1.5 mg/m²; day 1), carboplatin (age < 3 years, 18.6 mg/kg; age ≥ 3 years, 560 mg/m²; day 1), etoposide (age < 3 years, 5 mg/kg; age ≥ 3 years, 150 mg/m²; day 1–2). Post-surgical chemotherapy was sustained for 3–4 cycles. Radiotherapy was performed for children over 3 years old after post-surgical chemotherapy, and the radiotherapy dose of orbital was 36–45 Gy. Chemotherapy was continued after radiotherapy, and the total chemotherapy cycle was 16–18.

In each cycle of the chemotherapy, lumbar puncture and intrathecal injection were performed for each patient with methotrexate (MTX), cytosine arabinoside (Ara-c), and dexamethasone (Dex) according to the following regimen: age < 12 months: MTX (5.0 mg), Ara-c (12.0 mg), Dex (2.0 mg); age 12–24 months: MTX (7.5 mg), Ara-c (15.0 mg), Dex (2.0 mg); age 2–3 years: MTX (10.0 mg), Ara-c (25.0 mg), Dex (5.0 mg); age 3–12 years: MTX (12.5 mg), Ara-c (35.0 mg), Dex (5.0 mg); age > 12 years: MTX (12.5 mg), Ara-c (35.0 mg), Dex (5.0 mg).

Clinical assessment and follow-up
During the treatment period, routine CSF cytology examination was performed before each cycle of the chemotherapy, and fundus examinations and orbital MRI were performed every 4–8 weeks. Follow up every 3 months in the first 1–2 years, every 6 months in the 3–5 years, and once a year from the 6th year after treatment. During follow-up, we monitored patients for tumor recurrence though fundus examinations and orbital MRI. The prognosis of patients was indicated by the overall survival (OS). OS was calculated from the day of first admission to hospital to the time of the last follow-up or death.

Statistical analysis
All statistical analyses were performed by using SPSS version 22.0 (SPSS Institute. IL.USA). Quantitative data were expressed as means ± standard deviations (SD). Qualitative data were expressed as number and percentage and were compared using Fisher’s exact test. Survival curves were calculated by Kaplan-Meier method. Statistical significance was set at \( p < 0.05 \).

Results
Baseline characteristics
A total of 14 children (7 males, 7 females; median age: 41.03 months; range from 22.85 to 121.97 months) with unilateral RB and intracranial segment of retrobulbar optic nerve invasion were enrolled in this retrospective study from January 2009 to December 2018. The baseline characteristics of included patients were showed in Tables 1 and 2. The majority of cases were diagnosed after the age of 3 years (78.6%). All patients were found to be at stage IV. Leukocoria was the most common presenting sign in the diagnosis early RB, accounting for 42.9% (6/14). The median time from first symptom to diagnosis was 3.79 months, with most patients (11/14, 78.6%) diagnosed more than four weeks after first symptom. Bone marrow examinations were negative in all patients. Most patients (10/14, 71.4%) came from first-tier cities in China. Seventy-one percent of the tumors were in the left eye, and 28.6% were in the right eye (Fig. 1).

Clinical characteristics
Orbital MRI in all patients showed abnormal intraocular signal, thickened and enhanced optic nerve invaded the intraorbital, intracanalicular and intracranial segment. In addition, the optic nerve extends from the eyeball to the intracranial, so the intracranial optic nerve invasion must involve the intraorbital and intracanalicular invasion. Moreover, tumor cell invasion was found in the cut end of optic nerve of all patients after eye enucleation.

![Fig. 1](image-url)
In addition, 8 patients had choroidal invasion, 3 patients had scleral invasion, 2 patients had scleral invasion. Representative orbital MRI results of unilateral RB patients with intracranial segment of retrobulbar optic nerve invasion were shown in Fig. 2. As shown in Table 2, all patients had serum NSE values above the normal reference range (0–15.2 ng/dl) before treatment, with a median serum NSE value of 23.95 ng/dl (range, 15.7–65.0 ng/dl). The median value of NSE in CSF was 11.25 ng/dl (range, 5.3–294.7 ng/dl), of which 6 cases were higher than the normal reference range (0–10.1 ng/dl). The pathology of CSF in 2 cases with significantly elevated NSE indicated small round malignant cells (Fig. 3). In addition, the median serum LDH value was 409.5 U/L (range, 124–2244 U/L), of which 5 cases were higher than the normal reference range (0–245 U/L).

**Treatment and prognosis**
Among the 14 patients, 2 (14.3%) were administered with chemotherapy combined with intrathecal therapy, 3 (21.4%) with chemotherapy, eye enucleation and...
intrathecal therapy, 9 (64.3%) with chemotherapy, eye enucleation, radiotherapy and intrathecal therapy (Table 2).

The patients were followed up to December 2019, with a median follow-up of 20.6 months (range, 10.4–73.58 months). At the study closing date, there were 9 patients alive, 5 patients had died due to meningeal metastasis. The mean disease specific survival was 48.99 ± 8.62 months, and the OS rate was 64.3% (Fig. 4a).

Radiotherapy was associated with a longer disease specific survival (OS, 66.7 ± 6.5 months) compared with non-radiotherapy (OS, 22.6 ± 6.4 months, \( p = 0.023 \)) (Fig. 4b). Considering the therapeutic regimen (Fig. 4c), the OS of patients received comprehensive therapeutic regimen (chemotherapy, radiotherapy, surgery and intrathecal injection) was longer than that of patients received other therapeutic regimen (66.7 ± 6.5 vs. 22.6 ± 6.4 months, \( p = 0.047 \)). No statistically significant differences in OS were identified when the study group was divided by age (age < 3 and ≥ 3 years, 34.7 ± 16.0 vs. 44.5 ± 7.2 months, \( p = 0.281 \), Fig. 4d).

Discussion

RB is the most common intraocular malignancy in childhood, which seriously endangers children’s vision and life [12]. Optic nerve invasion has been found to be correlated with worse survival rate in RB patients [13]. In addition, patients with unilateral RB and intracranial segment of optic nerve invasion are extremely rare. In this study, we aimed to retrospectively analyze the clinical characteristics, treatment and prognosis of children with unilateral RB and intracranial segment of retrobulbar optic nerve invasion.

Diagnosis of RB was usually clear from clinical examination and presenting signs [14]. The most
common sign was leukocoria and strabismus [10]. In this study, we found that 42.9% of patients presented with leukocoria, and 21.4% with strabismus. Based on a large data from USA, the mean age at diagnosis of RB was 18 months, with unilateral cases diagnosing at a mean age of 24 months and bilateral diagnosing at 12 months [15]. In a study of 1457 cases of RB from Indian, the mean age at diagnosis was 29 months, with unilateral cases diagnosing at a mean age of 34 months and bilateral at 21 months [16]. Compared with developed countries, the diagnosis of RB in developing countries was usually delayed [17]. In this study, we found that the mean age at diagnosis was 22.85 months in unilateral cases, which consistent with the reports from USA. The possible reason was that most patients (71.4%) came from first-tier cities (Beijing, Tianjin, Shanghai, Chongqing, etc) in China. These cities were more medical-developed than other regions in the Chinese Mainland.

Treatment strategies for RB involved chemotherapy, radiotherapy and surgical enucleation [18]. Sullivan et al. performed a prospective, graduated intensity approach for adjuvant therapy based on pathologic findings of primarily enucleated eyes in patients with unilateral RB [19]. They found that patients in the high risk groups (pathology showed sclera invasion and/or tumor at the cut end of the optic nerve) were successfully treated with no evidence of recurrence after only six courses (each course of chemotherapy was 21 days) of adjuvant chemotherapy. Since the children in this group had been diagnosed with the intracranial segment of optic nerve invasion, the treatment methods were mainly systemic chemotherapy, radiotherapy, eye enucleation, and intrathecal therapy in each cycle of the chemotherapy. A total of 9 patients received comprehensive therapeutic regimen (chemotherapy, eye enucleation, radiotherapy and intrathecal therapy). After 20 months of follow-up, the OS rate improved to 64.3%, which was higher than that reported by Gunduz et al. [20]. They found that all patients with distant and CNS metastasis were deceased during a mean follow-up of 24 months (range, 4–62 months). In addition, we also found that radiotherapy and comprehensive therapeutic regimen were associated with a longer disease specific survival. At the study closing date, there were 9 patients (all received comprehensive therapeutic regimen) alive, 5 patients (4 did not receive radiotherapy and 2 did not receive eye enucleation) had died due to meningeal metastasis. These results indicated that patients with intracranial segment of optic nerve invasion should be treated comprehensively to obtain better clinical effect.

Conclusions
The overall prognosis of unilateral RB patients with intracranial segment of retrobulbar optic nerve invasion was poor. Chemotherapy and surgical treatment were necessary, but more attention should be paid to radiotherapy and intrathecal injection for improving prognosis.

Abbreviations
RB: Retinoblastoma; MRI: Magnetic resonance imaging; OS: Overall survival; CT: Computed tomography; CSF: Cerebrospinal fluid; ICRB: International Classification of Retinoblastoma; NSE: Neuron specific enolase; LDH: Lactate dehydrogenase; MTX: Patient with methotrexate; Ara-c: Cytosine arabinoside; Dex: Dexamethasone; SD: Mean±standard deviations

Acknowledgments
None.

Authors’ contributions
Conception and design, Y.W. and Y.Z.; Data collection, Y.W, Y.Z. and H.G.; Data analysis and interpretation, Y.W. and Y.Z.; Providing materials and samples, Y.W., J.M., B.L. and X.X.; Drafting article, Y.W. and Y.Z.; Approval of article, D.H.; Administrative support, D.H. and J.S. All the authors have read and approved the final manuscript.

Funding
This work was supported by Key Project Sub-Project of Pediatric Collaborative Center of Beijing Hospital Authority [number XT20180203] and Beijing Municipal Hospital Authority “Summit” talent program [number DFL20180201].

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the ethics committee of the Beijing Tongren Hospital, Capital Medical University (number, TRECKY2019-034). Written informed consent was obtained from all participants and their guardians.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interest.

Author details
1Department of Pediatrics, Beijing Tongren Hospital, Capital Medical University, No. 2, Xihuan South Road, Yihua Economic and Technological Development Zone, Beijing 100176, China. 2Department of Ophthalmology Oncology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. 3Department of Ophthalmology Science, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Received: 7 May 2020 Accepted: 14 December 2020
Published online: 14 January 2021

References
1. Fabian ID, Onadim Z, Karaa E, Duncan C, Chowdhury T, Scheiberg I, Ohnuma SI, Reddy MA, Sagoo MS. The management of retinoblastoma. Oncogene. 2018;37(12):1551–60.
2. Aerts I, Lumbroso-Le Roux L, Gauthier-Villars M, Brise H, Doz F, Desjardins L. Retinoblastoma. Orphanet J Rare Dis. 2006;1:31.
3. Rao R, Honavar SG. Retinoblastoma. Indian J Pediatr. 2017;84(12):937–44.
4. Ortiz MV, Dunkel IJ. Retinoblastoma. J Child Neurol. 2016;31(2):227–36.
5. Chawla B, Khurana S, Sen S, Sharma S. Clinical misdiagnosis of retinoblastoma in Indian children. Br J Ophthalmol. 2014;98(4):488–93.
6. Gao J, Zeng J, Guo B, He W, Chen J, Lu F, Chen D. Clinical presentation and treatment outcome of retinoblastoma in children of South Western China. Medicine (Baltimore). 2016;95(42):e5204.

7. Jin L, Zhang W, Pan H, Li T, Liu B, Zhao J, Wang B. Retrospective investigation of retinoblastoma in Chinese patients. Oncotarget. 2017;8(65):108402–7.

8. Shang W, Yang Y, Zhang J, Wu Q. Long noncording RNA BDNF-AS is a potential biomarker and regulates cancer development in human retinoblastoma. Biochem Biophys Res Commun. 2018;497(4):1142–8.

9. Hu H, Zhang W, Wang Y, Huang D, Shi J, Li B, Zhang Y, Zhou Y. Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis. BMC Ophthalmol. 2018;18(1):107.

10. Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, Abramson DH, Shields CL, Chantada GL, NJuguna F, et al. Retinoblastoma. Nat Rev Dis Primers. 2015;1:15021.

11. Chantada G, Doz F, Antoneli CB, Grundy R, Clare Stannard FF, Dunkel IJ, Giabowski E, Leal-Leal C, Rodriguez-Galindo C, Schwartzman E, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer. 2006;47(6):801–5.

12. Golabchi K, Soleimani-Jelodar R, Aghaoodost N, Momeni F, Moridikia A, Nahand JS, Masoudifar A, Razmjoo H, Mirzaei H. MicroRNAs in retinoblastoma: potential diagnostic and therapeutic biomarkers. J Cell Physiol. 2018;233(4):3016–23.

13. Kim U, Rathi G, Chowdhary G, Srinavasan KG, Shanthi R, Krishna RSP. Accuracy of preoperative imaging in predicting optic nerve invasion in retinoblastoma: a retrospective study. Indian J Ophthalmol. 2019;67(12):2019–22.

14. Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS, Gallie BL. Retinoblastoma. Lancet (London, England). 2012;379(9824):1436–46.

15. Abramson DH, Frank CM, Susman M, Whalen MP, Dunkel IJ, Boyd NW 3rd. Presenting signs of retinoblastoma. J Pediatr. 1998;132(3 Pt 1):505–8.

16. Kaliki S, Patel A, Iram S, Ramappa G, Mohamed A, Pallonja VAR. RETINOBLASTOMA IN INDIA: Clinical Presentation and Outcome in 1,457 Patients (2,074 Eyes). Retina (Philadelphia, Pa). 2019;39(2):379–91.

17. Goddard AG, Kingston JE, Hungerford JL. Delay in diagnosis of retinoblastoma: risk factors and treatment outcome. Br J Ophthalmol. 1999;83(12):1320–3.

18. Mendoza PR, Grossniklaus HE. Therapeutic options for retinoblastoma. Cancer Control. 2016;23(2):99–109.

19. Sullivan EM, Wilson MW, Billups CA, Wu J, Merchant TE, Brennan RC, Haik BG, Shukin B, Free TM, Given V, et al. Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. J Pediatr Hematol Oncol. 2014;36(6):e335–40.

20. Gunduz K, Muftuoglu G, Gunaip D, Unal E, Tacyildiz N. Metastatic retinoblastoma clinical features, treatment, and prognosis. Ophthalmolgy. 2006;113(9):1558–66.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.